Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trial

BACKGROUND: The effectiveness of combination therapy for COVID-19 pneumonia remains unclear. We evaluated favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia. METHODS: In this open-label phase 3 study, hospitalized adults who were positive for SARS...

Descripción completa

Detalles Bibliográficos
Autores principales: Terada, Jiro, Fujita, Retsu, Kawahara, Takuya, Hirasawa, Yasutaka, Kinoshita, Taku, Takeshita, Yuichiro, Isaka, Yuri, Kinouchi, Toru, Tajima, Hiroshi, Tada, Yuji, Tsushima, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165527/
https://www.ncbi.nlm.nih.gov/pubmed/35692220
http://dx.doi.org/10.1016/j.eclinm.2022.101484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165527/
https://www.ncbi.nlm.nih.gov/pubmed/35692220
http://dx.doi.org/10.1016/j.eclinm.2022.101484

Ejemplares similares